ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      64,006.07
      1.78%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. ARS Pharmaceuticals Inc (SPRY)

      7. ARS Pharmaceuticals Inc (SPRY) News

      SPRY

      ARS Pharmaceuticals (SPRY)

      ARS Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SPRY
      DateTimeSourceHeadlineSymbolCompany
      04/30/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
      04/03/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
      03/21/20244:05PMGlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
      03/07/20244:05PMGlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
      03/07/202412:56PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
      03/06/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
      03/01/20248:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      02/28/20249:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      02/26/202412:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      02/26/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
      02/22/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
      02/20/20249:01AMGlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
      02/05/20249:01AMGlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
      01/04/20244:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      01/04/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      01/04/20244:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      01/04/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
      11/09/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
      11/09/20234:00PMGlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
      11/09/202311:02AMGlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
      10/06/20239:57AMDow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
      10/06/20239:03AMGlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
      10/03/20239:03AMGlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
      09/25/20234:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
      09/20/202310:20AMDow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
      09/20/20236:30AMDow Jones NewsARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy SprayNASDAQ:SPRYARS Pharmaceuticals Inc
      09/20/20236:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
      09/19/202310:49PMGlobeNewswire Inc.FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyNASDAQ:SPRYARS Pharmaceuticals Inc
      09/01/20234:15PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRYARS Pharmaceuticals Inc
      08/10/20234:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRYARS Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:SPRY